JP5514733B2 - 療法に対する応答を予測するための方法 - Google Patents

療法に対する応答を予測するための方法 Download PDF

Info

Publication number
JP5514733B2
JP5514733B2 JP2010537899A JP2010537899A JP5514733B2 JP 5514733 B2 JP5514733 B2 JP 5514733B2 JP 2010537899 A JP2010537899 A JP 2010537899A JP 2010537899 A JP2010537899 A JP 2010537899A JP 5514733 B2 JP5514733 B2 JP 5514733B2
Authority
JP
Japan
Prior art keywords
steroid
seq
marker gene
primer
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010537899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011505829A (ja
JP2011505829A5 (enExample
Inventor
コウズネットソフ，ニコライ
バンドホルツ，リサ・シャルロッタ
ギーレン，アレクサンダー
ヴォン，ステイン・オリバー
ヴォン，ステイン・ペトラ
Original Assignee
インデックス・ファーマシューティカルズ・アクチエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インデックス・ファーマシューティカルズ・アクチエボラーグ filed Critical インデックス・ファーマシューティカルズ・アクチエボラーグ
Publication of JP2011505829A publication Critical patent/JP2011505829A/ja
Publication of JP2011505829A5 publication Critical patent/JP2011505829A5/ja
Application granted granted Critical
Publication of JP5514733B2 publication Critical patent/JP5514733B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010537899A 2007-12-14 2008-12-12 療法に対する応答を予測するための方法 Active JP5514733B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0702789 2007-12-14
SE0702789-9 2007-12-14
PCT/SE2008/051446 WO2009078793A1 (en) 2007-12-14 2008-12-12 Method for predicting the response to a therapy

Publications (3)

Publication Number Publication Date
JP2011505829A JP2011505829A (ja) 2011-03-03
JP2011505829A5 JP2011505829A5 (enExample) 2012-02-02
JP5514733B2 true JP5514733B2 (ja) 2014-06-04

Family

ID=40795763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010537899A Active JP5514733B2 (ja) 2007-12-14 2008-12-12 療法に対する応答を予測するための方法

Country Status (6)

Country Link
US (2) US8574834B2 (enExample)
EP (1) EP2220489B1 (enExample)
JP (1) JP5514733B2 (enExample)
AU (1) AU2008339090A1 (enExample)
CA (1) CA2708267C (enExample)
WO (1) WO2009078793A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140030735A1 (en) * 2011-03-07 2014-01-30 Temple University - Of The Commonwealth System Of Higher Education Biomarkers of chronic obstructive pulmonary disease
US11560594B2 (en) * 2015-02-05 2023-01-24 Duke University Methods of detecting osteoarthritis and predicting progression thereof
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
US20200360364A1 (en) * 2018-01-31 2020-11-19 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using chrna6 activators
WO2022246048A2 (en) * 2021-05-20 2022-11-24 Trustees Of Boston University Methods and compositions relating to airway dysfunction
JP7710407B2 (ja) * 2022-03-31 2025-07-18 日立建機株式会社 作業機械

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002300883A (ja) * 2001-04-05 2002-10-15 Jenokkusu Soyaku Kenkyusho:Kk ステロイド応答性の検査方法
US7384736B2 (en) 2001-09-06 2008-06-10 Decode Genetics Ehf. Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
AU2003212822A1 (en) 2002-01-22 2003-09-02 Trustees Of The University Of Pennsylvania Methods for determining drug responsiveness
WO2005116268A2 (en) * 2004-05-27 2005-12-08 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Differential expression of molecules associated with acute stroke
DE602006015963D1 (de) * 2005-07-01 2010-09-16 Index Pharmaceuticals Ab Immunstimulatorisches verfahren
AU2006306805A1 (en) 2005-10-28 2007-05-03 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
WO2008051290A2 (en) 2006-04-07 2008-05-02 Xdx, Inc. Steroid responsive nucleic acid expression and prediction of disease activity

Also Published As

Publication number Publication date
US20140030723A1 (en) 2014-01-30
AU2008339090A1 (en) 2009-06-25
WO2009078793A1 (en) 2009-06-25
CA2708267A1 (en) 2009-06-25
CA2708267C (en) 2016-05-10
JP2011505829A (ja) 2011-03-03
US8574834B2 (en) 2013-11-05
EP2220489B1 (en) 2015-02-18
EP2220489A4 (en) 2011-02-09
EP2220489A1 (en) 2010-08-25
AU2008339090A2 (en) 2010-09-02
US20100285477A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
US9164094B2 (en) Biomarkers to identify HIV-specific T-cell subsets
JP5514733B2 (ja) 療法に対する応答を予測するための方法
US20200103418A1 (en) Diagnostic and therapeutic methods for irak4-mediated disorders and conditions
Hua et al. Aberrant expression of microRNA in CD4+ cells contributes to Th17/Treg imbalance in primary immune thrombocytopenia
Aplin et al. Regulation of angiogenesis, mural cell recruitment and adventitial macrophage behavior by Toll-like receptors
EP2513336B1 (en) Method for characterizing host immune function by ex vivo induction of offensive and defensive immune markers
US20080300147A1 (en) Detection and Treatment of Fibrotic Disorders
Mahdian et al. Macrophage migration inhibitory factor as a potential biomarker of endometriosis
Wang et al. MicroRNA microarray-based identification of involvement of miR-155 and miR-19a in development of oral lichen planus (OLP) by modulating Th1/Th2 balance via targeting eNOS and toll-like receptor 2 (TLR2)
Turrel-Davin et al. FoxO3a involved in neutrophil and T cell survival is overexpressed in rheumatoid blood and synovial tissue
US20250034650A1 (en) Transcriptional biomarkers for response to innate immune activators
Zeng et al. Inflammatory and immune-related factor Caspase 1 contributes to the development of oral lichen planus
RU2672595C2 (ru) Способ диагностики молекулярного фенотипа пациента, страдающего заболеванием, сопровождающимся хроническими воспалениями
US20230014092A1 (en) Materials and methods for monitoring inflammation
US20230003719A1 (en) Materials and methods for inflammatory molecular markers
Tanha et al. 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin potential impacts on peripheral blood mononuclear cells of endometriosis women
Shelton et al. Immunopathogenic pathways in canine inflammatory myopathies resemble human myositis
Qian et al. Differential expression of immune checkpoints (OX40/OX40L and PD-1/PD-L1) in decidua of unexplained recurrent spontaneous abortion women
WO2020016888A9 (en) Determining responders to inflammation treatment
US20120164639A1 (en) Methods for detecting low grade inflammation
KR102202120B1 (ko) 알츠하이머 질환의 진단 또는 치료를 위한 Ｕｂｅ２ｈ의 용도
JP2011004619A (ja) 免疫疾患の検査方法、及び免疫疾患の予防又は治療薬のスクリーニング方法
KR101883788B1 (ko) 메토트렉세이트의 치료 반응성 진단용 조성물 및 이를 이용한 진단 방법
TW202444358A (zh) 診斷及治療多發性硬化症的方法
US20100069343A1 (en) Methods of predicting steroid responsiveness with Il-1RII

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131016

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131028

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140331

R150 Certificate of patent or registration of utility model

Ref document number: 5514733

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250